Job Posting: Sector Innovation Coordinator

Sector Innovation Coordinator

Reporting to the Director, Sector Innovation, the newly created Sector Innovation Coordinator position is responsible for coordinating key aspects of Genome Atlantic’s business development efforts by playing an important connector role in helping to strengthen existing client relationships while supporting the development of new opportunities and partner relationships.

The Sector Innovation Coordinator is actively engaged, across all sectors, to help to find and research new leads and actively support Business Development activities. From coordinating team efforts to managing meeting logistics, participating in meetings and ensuring prompt follow-up — no two days are alike! This position plays an important role in proposal development and managing project timelines and key deliverables. From time to time, the Sector Innovation Coordinator is called upon to attend and represent Genome Atlantic at select conferences, workshops and special events.

Based out of our Halifax office, this opportunity is ideal for a highly organized and genuine team player known for delivering excellence in a fast-paced environment, while pursuing multiple opportunities simultaneously. Excellent written, verbal and interpersonal communication skills are essential to succeed in this role. A respectful critical thinker with a great sense of humour will feel right at home on our team!

Key Qualifications

  • Bachelor’s degree (BSc, Engineering, Business) or equivalent combination of education and experience
  • Minimum of 3-5 years of directly relevant work experience, preferably related to science and technology
  • Prior academic research experience and exposure to the Bioscience sector are considered assets
  • Solid project management skills and an unwavering commitment to follow-up and follow-through
  • Sound technical skills including proficiency in MS Office suite
  • Prior business writing and proposal development experience preferred
  • Experience with CRMs would be considered an asset
  • Experience working with government agencies and funding partners would be a plus

How to Apply

Kindly forward your cover letter and resume (as one document) with the heading “Sector Innovation Coordinator” in the subject line of your email to ktweel@genomeatlantic.ca. Please entitle all attachments to include your first and last name. Your cover letter should articulate why you believe you are a fit for this position, key career accomplishments relevant to this opportunity, and how you see yourself contributing to our team dynamic.

Closing date for priority selection is Sunday, July 12th, 2020 however we will continue to accept resumes after this date until the position is filled.
Individual accommodations due to a disability are available upon request for candidates taking part in all aspects of the selection process. All qualified applicants will receive consideration for employment without regard to age, race, religion, ethnicity, gender, disability, citizenship status, marital status, actual or perceived sexual orientation.
Genome Atlantic is committed to creating an inclusive environment and building a team that represents a variety of backgrounds, perspectives, and skills. We value diversity and recognize that experience comes in many forms and skills are transferable. Please view this description as a general overview, but not a mandatory comprehensive list. If you feel passionate about our efforts and believe that you have the skills to contribute and lead in this role, apply!

We thank all interested parties; however, only those applicants under consideration will be contacted.

About Genome Atlantic

Genomics is a powerful combination of genetics, biology and computer science. It provides us with the unprecedented ability to better understand all living things, leading to a host of opportunities across a variety of sectors. Genome Atlantic is a not-for-profit corporation with a mission to develop and lead a program of genomics R&D that delivers tangible economic, social and environmental benefits to Atlantic Canada.

We connect ideas and people across public and private sectors to find new uses for genomics, invest in large-scale science and technology to fuel innovation, and translate discoveries into solutions across key sectors of national importance. Key sectors include health, agriculture and agri-food, forestry, fisheries and aquaculture, the environment, energy, and mining. Together with our many partners, we have enabled over $120 million in strategic R&D since our inception in 2000.

Regional genomics projects get funding for COVID-19

Halifax, NS – Two teams of Dalhousie University scientists are receiving more than $300,000 in funding for genomics research into critical areas in the battle against COVID-19.  Drs. David Kelvin and Alyson Kelvin (also IWK Health Centre) are pursuing biomarkers for COVID-19 that could predict disease severity; while Drs. Nikhil Thomas, John Archibald and Morgan Langille will pilot an innovative protocol for large-scale surveillance testing.  Both projects are supported by Genome Atlantic with $250,000 in funding from Genome Canada’s COVID-19 Regional Genomics Initiative, with an additional $60,000 provided by Research Nova Scotia to the Thomas project. This new Genome Canada money augments existing funding to the Kelvin project in their search for biomarkers, including funding from Research Nova Scotia provided earlier this year.

Genomics plays an important role in COVID-19 research, from detecting infections and understanding how the virus mutates, to tracking these mutations and developing vaccines and treatments.  Through the COVID-19 Regional Genomics Initiative, Genome Canada and regional Genome Centres across the country are responding to the urgent need for further research.

Drs. David and Alyson Kelvin are at the forefront of an international effort to find biomarkers associated with mild, severe and critically ill patients.  This funding will enable the expansion of current work to include a set of patient samples collected during the outbreak at Northwood long-term care facility. Collaborators include Drs. Melissa Andrew, Ken Rockwood, Sam Suriel, Lisa Barrett, and Barry Clarke (Dalhousie/Nova Scotia Health Authority); Mark Cameron and Cheryl Cameron (United States); and Jesus Bermejo Martin and Salvador Reno Garcia (Spain). This international team will develop and contribute to rapid and reliable patient assessment tools, protocols and Point of Care Devices which utilize biomarkers identified from their work. These tools could help doctors triage patients and inform treatment protocols in a variety of settings including emergency rooms, hospitals, long-term care facilities and ICUs.

The Chief Medical Officer of Canada has identified an urgent need to ramp up COVID-19 testing capacity to support the re-opening of the economy.  While standard diagnostic testing is primarily used for people who are symptomatic or a close contact of a COVID-positive individual, the model piloted by the Thomas-Archibald-Langille team is a surveillance tool that could quickly identify early trends in transmission in high risk settings like long-term care or in workplaces where physical distancing is impossible such as fishing vessels or food processing facilities. Individuals who test positive would then be sent to hospital for a diagnostic test. This new model represents a simple, quick and relatively cheap way to identify hidden chains of transmission in at-risk populations.  

“Canadian scientists are at the forefront of the global race to fight COVID-19. Genome Atlantic is proud to support local scientists who are helping lead the charge, and we thank our funding partners Genome Canada and Research Nova Scotia for enabling this important research,” says Genome Atlantic President and CEO Dr. Steve Armstrong.

Part 1: On the Trail of COVID-1

Part 2: The Race for a Vaccine

-30-

Genome Atlantic is a not-for-profit corporation with a mission to help Atlantic Canada reap the economic and social benefits of genomics technologies.  Since its inception in 2000, the corporation has worked with a range of private and public-sector partners to enable more than $120 million in new genomics R&D. To learn more, visit www.genomeatlantic.ca

Contact:  Charmaine Gaudet, Director of External Relations, 902-488-7837/cgaudet@genomeatlantic.ca